MDCL - After Recent M&A Activity Medicine Man Is Undervalued
After the recent announcement of acquisitions, Medicine Man (MDCL) could be trading at 6x sales. Considering that competitors in the cannabis industry are trading at 9x-47x sales, Medicine Man seems to be very undervalued. Since the new transactions were announced in September, the share price increased by more than 25%. We believe that the upward trend may continue.
Business
Founded in 2014, Medicine Man is a cannabis consulting company providing services about cost-efficient cultivation technologies, and dispensary operating solutions among others. The image and the lines below describe Medicine Man's business model in